Genmab Announces Phase 3 Study Evaluating Epcoritamab in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma
Company Announcement First Phase 3 study of epcoritamab as part of broad clinical development plan with AbbVie Diffuse Large B-cell Lymphoma is the most common form of non-Hodgkin’s lymphoma worldwide Copenhagen, Denmark; November 5, 2020 – Genmab A/S ( …